The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Share News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sensyne reports "disappointing" first half, with revenue decline

Mon, 31st Jan 2022 11:13

(Alliance News) - Sensyne Health PLC said on Monday that revenue fell year-on-year in the first half of its financial year, as losses widened following a "challenging" period for the clinical artificial intelligence company.

The Oxford, England-based firm reported a pretax loss of GBP21.1 million for the six months ended October 31, widening from GBP13.8 million in the same period a year prior.

Revenue had more than halved for the period, down 57% year-on-year to GBP1.0 million, from GBP2.3 million. Revenue came mostly from a contract for AI medical imaging app MagnifEye with the Department for Health & Social Care, a life science agreement with Bristol Myers Squibb, and uptake of sales in GDm-Health, a remote monitoring app for gestational diabetes patients.

"Whilst our commercial progress in the year to date has been disappointing, we remain confident about the company's long-term prospects, given the size of our database, the strength of our medical and data science expertise, the growth of our business development pipeline, and the significant interest Sensight is now generating from potential customers," said Chief Executive Officer Paul Drayson.

Operating expenses were up 44% in the period, as the company increased its headcount for research and development in its Sensight data analytics platform. Gross margin relative to revenue fell during the period to 44% from 58%, owing to a change in sales mix of agreements with life science clients.

Cash on October 31 was GBP8.1 million, down from GBP18.6 million on October 31, 2020.

The company announced it had secured of GBP11.4 million in much-needed financing for its short term needs on Wednesday. However, it said customers may have to wait until its long-term financial position is clarified before confirming orders. It believes up to GBP26 million of contracts could be brought in during the financial year, but this could be "very materially lower" if its long-term financial outlook remains precarious.

Sensyne's share price fell 5.9% to 19.30 pence each in London on Monday morning. It has fallen 76% in value since the start of 2022.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 Sep 2021 12:29

Sensyne Health signs five-year research deal with GOSH

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health has signed a five-year non-exclusive strategic research agreement with the Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), it announced on Thursday, to analyse anonymised patient data using clinical AI technology.

Read more
19 Aug 2021 12:50

TRADING UPDATES: Resolute books hefty impairments; tinyBuild buys

TRADING UPDATES: Resolute books hefty impairments; tinyBuild buys

Read more
10 Aug 2021 19:24

TRADING UPDATES: Barkby expects revenue growth; Beeks trading in line

TRADING UPDATES: Barkby expects revenue growth; Beeks trading in line

Read more
2 Aug 2021 14:40

EXECUTIVE CHANGES: 88 Energy appoints new COO, chair and non-executive

EXECUTIVE CHANGES: 88 Energy appoints new COO, chair and non-executive

Read more
2 Aug 2021 11:41

IN BRIEF: Sensyne reaches dataset access of over 60 million patients

IN BRIEF: Sensyne reaches dataset access of over 60 million patients

Read more
22 Jul 2021 14:29

EXECUTIVE CHANGES: Nuformix responds to "frustration" as CEO departs

EXECUTIVE CHANGES: Nuformix responds to "frustration" as CEO departs

Read more
22 Jul 2021 12:26

Sensyne Health appoints new scientific chief

(Sharecast News) - Artificial intelligence (AI) company Sensyne Health announced the appointment of Dr David Ruau to the newly-created role of chief scientific officer on Thursday, with effect from 1 September.

Read more
19 Jul 2021 19:13

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

Read more
18 Jun 2021 15:39

EXECUTIVE CHANGES: Trident Royalties picks ex-Glencore member as chair

EXECUTIVE CHANGES: Trident Royalties picks ex-Glencore member as chair

Read more
1 Jun 2021 20:24

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Read more
27 May 2021 20:17

TRADING UPDATES: Brave Bison, Strix Group see strong performances

TRADING UPDATES: Brave Bison, Strix Group see strong performances

Read more
27 May 2021 11:26

Sensyne Health FY trading comes in ahead of expectations

(Sharecast News) - Clinical AI company Sensyne Health said on Thursday that its full-year trading performance had come in ahead of expectations.

Read more
24 May 2021 19:23

TRADING UPDATES: HSBC issues bond notes; Zegona to return capital

TRADING UPDATES: HSBC issues bond notes; Zegona to return capital

Read more
24 May 2021 11:21

Sensyne signs second US strategic research deal

(Sharecast News) - Clinical artificial intelligence (AI) Sensyne Health has signed its second strategic research agreement in the United States, it announced on Monday, with the Colorado Center for Personalized Medicine (CCPM), a partnership between nonprofit health system UCHealth and the University of Colorado Anschutz Medical Campus.

Read more
21 May 2021 17:51

TRADING UPDATES: Arkle spots gold; SDCL seals USD177 million buy

TRADING UPDATES: Arkle spots gold; SDCL seals USD177 million buy

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.